Open AccessPREVALENCE AND IDENTIFICATION OF FLT3-ITD AND D835 ACTIVATING MUTATIONS IN ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN KASHMIRI PATIENTS (NORTH INDIA)
Author(s) -
Fozia Mohammad,
Arshad A. Pandith,
M. Vijay Kumar,
Aabid Koul,
Ina Amin,
Usma Manzoor,
Iqra Anwar,
Javid Rasool,
Sajad Geelani
Publication year - 2021
Publication title -
international journal of advanced research
Language(s) - English
Resource type - Journals
ISSN - 2320-5407
DOI - 10.21474/ijar01/12975
Subject(s) - biology , exon , mutation , missense mutation , point mutation , gene , leukemia , genetics , dasatinib , myeloid leukemia , cancer research , microbiology and biotechnology , imatinib
Background: The FLT3 gene, a receptor tyrosine kinase encodes a transmembrane protein that plays a fundamental role in normal hematopoiesis. The two types of mutations identified in FLT gene are an internal tandem duplication (FLT3-ITD) in exon 14 and 15, and a missense point mutation in codon 835 in exon 20 (FLT3-D835). These mutations activate a ligand independent constitutive tyrosine-kinase receptor and are mostly found in acute myeloid leukemia and are associated with bad prognosis. We first time from the Indian subcontinent evaluated the frequency of FLT3 mutations in a cohort of Acute lymphoid leukemia (ALL). Methods: FLT3-ITD mutations and FLT3-D835 were investigated in a cohort of 74 confirmed ALL patients at diagnosis, by polymerase chain reaction (PCR) and restriction fragment length-PCR (PCR-RFLP) respectively. Results: Overall 03 mutations were detected from 74 ALL patients (4.05%) in FLT-ITD but no mutation was found in FLT3-D835. All the three patients with FLT mutations were negative for the known translocation in ALL. Among these patients one died in the first year of treatment (33.4%) while the rest of two FLT3 mutant patients are fairly doing well. Conclusions: This report implies that FLT3 gene mutations are present in ALL patients from Kashmir (North India) although not as common as found in AML (20-30%) but do impact the clinical outcome.